Related Experiment Videos
Management of SSRI-induced sexual dysfunction
1Department of Pharmacy, Medical University of South Carolina, Charleston, USA.
The Annals of Pharmacotherapy
|November 24, 1998
Summary
Selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction is a common adverse effect, though controlled studies are needed to confirm prevalence. Management often involves serotonin antagonists and dopamine agonists, showing general effectiveness but requiring further research.
Area of Science:
- Psychiatry
- Pharmacology
- Sexual Medicine
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed antidepressants.
- Sexual dysfunction is a potential adverse effect of SSRI treatment.
- Understanding the incidence and management of SSRI-induced sexual dysfunction is crucial for patient care.
Purpose of the Study:
- To describe the occurrence of sexual dysfunction associated with SSRI use.
- To review reported cases of SSRI-induced sexual dysfunction.
- To outline current management strategies for this adverse effect.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE (1986-1998) and reference reviews.
- Key search terms included 'sexual dysfunction,' 'antidepressants,' and specific SSRI names.
- Twenty-one studies (2 open-label, 12 case series, 7 case reports) were analyzed, focusing on SSRI-induced sexual dysfunction over 3-24 weeks.
Main Results:
- SSRI-induced sexual dysfunction was reported with fluoxetine, paroxetine, sertraline, and fluvoxamine.
- Methodological limitations in existing studies include lack of control for gender, SSRI dose/duration, and concomitant medications.
- Data organization focused on pharmacologic agents, patient populations, SSRI types, dysfunction types, study design, and treatment outcomes.
Conclusions:
- The high frequency of reports suggests SSRI-induced sexual dysfunction is common, necessitating controlled prevalence studies.
- Fluoxetine is most frequently implicated, possibly due to its widespread use; further comparative studies are needed.
- Serotonin antagonists and dopamine agonists show general effectiveness in management but require rigorous controlled trials.